Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28041791 | 0.87 | — | — | |
| SCHEMBL3803757 | 0.81 | NPSR1 (0.42) | ALDH1A1NPSR1IMPDH2 | |
| SCHEMBL3277032 | 0.81 | GAA (0.39) | ALDH1A1TSHRNPSR1 | |
| SCHEMBL16511129 | 0.76 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHR | |
| SCHEMBL16510912 | 0.75 | ALDH1A1 (0.33) | ALDH1A1ALOX15TSHR | |
| SCHEMBL3258986 | 0.74 | KDM4E (0.33) | ALDH1A1NPSR1 | |
| SCHEMBL1350377 | 0.73 | ALDH1A1 (0.36) | ALDH1A1IMPDH2 | |
| SCHEMBL12495776 | 0.73 | NPSR1 (0.30) | NPSR1 | |
| SCHEMBL16511068 | 0.73 | LMNA (0.33) | ALDH1A1TSHR | |
| SCHEMBL4847932 | 0.73 | RXRA (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-05-08 | — | — | US | disclosed |
| CN-118946360-A | Bicyclic heteroarenes and methods of use thereof | 奇尼塔公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4444317-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2011152485-A1 | NOVEL 4,5-FUSED PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-12-08 | — | — | WO | disclosed |
| WO-2009085797-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7439240-B2 | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity | ASTRAZENECA AB (SE) | 2008-10-21 | — | — | US | disclosed |
| US-20080125426-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080119469-A1 | 1-(4-methylphenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine-6-carbonitrile; reversible inhibitors of cysteine proteases S, K, F, L, B; diseases associated with Cathepsin S; antiinflammatory agent, autoimmune diseases; asthma, rheumatoid arthritis, multiple sclerosis, Crohn's, Alzheimer's diseases | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| EP-1532148-B1 | NOVEL PURINE- OR PYRROLOL(2,3-D)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| US-20050203107-A1 | Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532148-A1 | NOVEL PURINE- OR PYRROLOL(2,3-D)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004000843-A1 | NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | ALDH1A1 1243/4885ALOX15 1628/4885TSHR 3951/4885 |
| US-20080119469-A1 | 1-(4-methylphenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine-6-carbonitrile; reversible inhibitors of cysteine proteases S, K, F, L, B; diseases associated with Cathepsin S; antiinflammatory agent, autoimmune diseases; asthma, rheumatoid arthritis, multiple sclerosis, Crohn's, Alzheimer's diseases | CTSS, CTSB, CTSL | ALDH1A1 2991/4885ALOX15 1736/4885TSHR 4376/4885 |
| US-20080125426-A1 | Novel Compounds | CTSS, CTSB, CTSF | ALDH1A1 3421/4885ALOX15 2460/4885TSHR 4591/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | ALDH1A1 3837/4885ALOX15 2470/4885TSHR 3647/4885 |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2E, POLR2H | ALDH1A1 1058/4885ALOX15 1799/4885TSHR 3854/4885 |
| US-20050203107-A1 | Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example | CTSB, CTSL, CTSS | ALDH1A1 1961/4885ALOX15 2294/4885TSHR 4431/4885 |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | TARDBP, TDP2, PSEN2 | ALDH1A1 2999/4885ALOX15 2407/4885TSHR 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.